And the fact that we have Contouring Assistant, and modifying that. That to be able to do a very quick treatment plan that could be really big customized to each prostate type. And, to be honest, I cannot stress that point enough, because prostate as you know can be smaller than 20CC’s and larger than 100CC’s. And not just the size, but also the shape really matters. And so to be able to use our technology and really custom design to be sure that none of the vitals functions are affected, and at the same time, enough tissue is ablated to be able to provide the patient with a durable treatment and do not have to worry about and see any cancer at that time, at least. I think that’s the value proposition. So I think again, I feel very good about it.
I think our team feels very good about it. I think that we will definitely start from the larger prostates, but I think we will over time look towards going into the mainstream as well.
Rahul Sarugaser: Okay, thank you again for taking our questions. We’ll get back in queue.
Arun Menawat: Thank you, Rahul.
Operator: Thank you one moment for the next question. Our next question comes from Ben Haynor of Alliance Global Partners. Your line is open.
Benjamin Haynor: Good afternoon gentlemen, thanks for taking my questions. First off for me, I was curious on the hybrid cases that are being done. Are those more kind of incidental where you have a patient that has prostate cancer and also BPH and they would be operated on. Anyway, is it more patients that might have been candidates for watchful waiting and that might be say great group one that are saying, well, let’s kill two birds with one stone here and do get rid of the cancer and hopefully solve the BPH as well, any color on that group of patients?
Arun Menawat: Yeah. Ben, I think you’re thinking in the right place. If you look at our data that we talk about every quarter, the number of patients who have early stage cancer and also have BPH, that’s a segment that has been growing for us. And as you know, cancer is not a monofocal disease. It’s a multifocal disease and we can wherever it resides we can get to it. And so the treatment designs that we are seeing for those types of patients are typically in the 50% to 80% ablation range, and they are ablating the tissue that normally causes the symptoms of BPH, and they’re most certainly targeting explicitly where the cancer resides, and there’s usually they add some safety margin to that so that there’s a high level of confidence that the cancer is taken care of and at the same time BPH is taken care of.
So it really is both that they look to do, so it’s a two for one. And as you might know, there’s a large population of patients who are on active surveillance, it’s million plus and these patients have also had BPH, many of them. And so that is the initial target market and I think that’s where that population that we’re starting to see is growing and will be our market entry.
Benjamin Haynor: Okay. That’s very helpful. Thank you for that. And then, I appreciate that you may not want to share kind of everything on this just yet, but on the BPH AI, I think it was Dr. Hong [ph] during the Investor Day talking about how if you are going to do a volume similar to what’s being done with TRIP [ph] today, you could get a procedure done with TULSA, bringing a similar volume in. I think you said less than an hour if I understood properly. Just curious if that is reasonably accurate. And then also, are the BPH cases that are being performed as we speak, are those informing what ultimately goes into the kind of contouring the system, BPH AI for the automation of the treatment plan down the road?
